Skip to content

Pro-Dex, Inc. PDEX Stock-Based Comp

Stock-Based Comp at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
$300M+4.2%
Stryker logo
StrykerSYK
$87M+3.6%
Zimmer Biomet Holdings logo
Zimmer Biomet HoldingsZBH
$24.2M+23.5%
Medtronic logo
MedtronicMDT
$95M+6.7%
InfuSystem Holdings logo
InfuSystem HoldingsINFU
$1.23M+11.3%
Orthofix Medical Inc. logo
Orthofix Medical Inc.OFIX
$6.53M+1.0%

Other financials

Income statement

See full
Revenue$19.9M+14.6%
Gross profit$6.1M+5.8%
Operating income$3.1M-15.0%
Net income$3.9M+20.2%
EPS (diluted)$1.20+22.4%

Balance sheet

See full
Cash & equivalents$10.0M+123%
Total debt$16.0M+43.2%
Total equity$45.2M+28.1%
Total assets$75.0M+16.7%

Cash flow

See full
Operating cash flow$1.6M+488%
CapEx$112.0K-37.8%
Free cash flow$1.5M

Valuation

See full
Market cap$195.81M+39.3%
Enterprise value$201.8M+34.4%
P/E16.3×+0.7×
P/S2.6×+0.5×

Profitability

See full
Gross margin27.8%-3.6pp
Operating margin14.5%-3.8pp
Net margin16.1%+1.5pp
FCF margin-3.8%+3.2pp

Returns & leverage

See full
Return on equity29.8%+1.5pp
Debt / equity0.4×0.0×
Current ratio3.7×+0.9×

Where this comes from

Reported directly by Pro-Dex, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The official record: Pro-Dex, Inc.’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Pro-Dex, Inc.'s stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Pro-Dex, Inc.'s stock-based comp?
Pro-Dex, Inc. (PDEX) reported stock-based comp of $186K in Q1 2026.
How has Pro-Dex, Inc.'s stock-based comp changed year-over-year?
Pro-Dex, Inc.'s stock-based comp increased by 17.7% year-over-year, from $158K to $186K.
What is the long-term trend for Pro-Dex, Inc.'s stock-based comp?
Over 3 years (2022 to 2025), Pro-Dex, Inc.'s stock-based comp has grown at a -24.2% compound annual growth rate (CAGR), from $1.28M to $555K.
What does stock-based comp mean?
Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.